Trial reportClinical drug investigation2013
Population pharmacokinetics of dexmedetomidine in critically ill patients.
Trial report in Clinical drug investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration.Clinical pharmacokinetics · 2020Trial
- Evaluation of pharmacokinetic models of intravenous dexmedetomidine in sedated patients under spinal anesthesia.Journal of anesthesia · 2018Trial
- Advances in pharmacokinetic-pharmacodynamic modeling for anesthesia, 1987-2024: a review.Frontiers in pharmacology · 2026Review
- Re-sedation using remimazolam anesthesia in patients with multiple injuries during recovery: a case report and literature review.Frontiers in medicine · 2025Article
- Using Real-World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and Infants.Journal of clinical pharmacology · 2024Article
- Variant-based heritability assessment of dexmedetomidine and fentanyl clearance in pediatric patients.Clinical and translational science · 2023Article
- Dexmedetomidine as an anesthetic adjunct is associated with reduced complications and cardiac intensive care unit length of stay after heart valve surgery.BMC anesthesiology · 2023Article
- A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults.Journal of clinical medicine · 2020Article
- Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.Critical care (London, England) · 2020Review
- Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation.Anesthesia and analgesia · 2020Article
- Recovery time after oral and maxillofacial ambulatory surgery with dexmedetomidine: an observational study.Clinical oral investigations · 2019Observational
- Dexmedetomidine Improves Cardiovascular and Ventilatory Outcomes in Critically Ill Patients: Basic and Clinical Approaches.Frontiers in pharmacology · 2019Review
- Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- The Effect of Intravenous Infusion of Dexmedetomidine to Prevent Bleeding During Functional Endoscopic Sinus Surgery: A Clinical Trial.Anesthesiology and pain medicine · 2017Article
- Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine.Clinical pharmacokinetics · 2017Review
- Treatment of Postoperative Pain in Pediatric Operations: Comparing the Efficiency of Bupivacaine, Bupivacaine-Dexmedetomidine and Bupivacaine-Fentanyl for Caudal Block.Anesthesiology and pain medicine · 2016Article
- Inhibition of the cardiac Na⁺ channel α-subunit Nav1.5 by propofol and dexmedetomidine.Naunyn-Schmiedeberg's archives of pharmacology · 2016Article
- Population Pharmacokinetics of Fentanyl in the Critically Ill.Critical care medicine · 2016Article
- Effective dose of dexmedetomidine to induce adequate sedation in elderly patients under spinal anesthesia.Korean journal of anesthesiology · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAlthough the pharmacokinetics of dexmedetomidine in healthy volunteers have been studied, there are limited data about the pharmacokinetics of long-term administration of dexmedetomidine in critically ill patients.
methodsThis population pharmacokinetic analysis was performed to quantify the pharmacokinetics of dexmedetomidine in critically ill patients following infusions up to 14 days in duration. The data consisted of three phase III studies (527 patients with sparse blood sampling, for a total of 2,144 samples). Covariates were included in a full random-effects covariate model and the most important covariate relationships were tested separately. The linearity of dexmedetomidine clearance was evaluated by observing steady-state plasma concentrations acquired at various infusion rates.
resultsThe data were adequately described with a one-compartment model. The clearance of dexmedetomidine was 39 (95 % CI 37-41) L/h and volume of distribution 104 (95 % CI 93-115) L. Both clearance and volume of distribution were highly variable between patients (coefficients of variation of 62 and 57 %, respectively), which highlights the importance of dose titration by response. Covariate analysis showed a strong correlation between body weight and clearance of dexmedetomidine. The clearance of dexmedetomidine was constant in the dose range 0.2-1.4 μg/kg/h.
conclusionsThe pharmacokinetics of dexmedetomidine are dose-proportional in prolonged infusions when dosing rates of 0.2-1.4 μg/kg/h, recommended by the Dexdor(®) summary of product characteristics, are used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.